What is the latest market price of Apelis? Analysis of price differences between different versions

Alpelisib (Alpelisib) is a drug used to treat PIK3CA mutation-positive breast cancer. It is mainly used for patients with advanced or metastatic breast cancer. Although the drug has been approved and launched in the international market, it has not yet been officially launched in mainland China. Therefore, domestic patients cannot purchase it directly through domestic channels. For patients who urgently need the drug, they can only purchase it through imported drug channels or abroad, but this also results in very high drug costs for patients.

According to existing market information, the price of the Indian version of Apelis’ original drug is about more than 3,000 yuan. The price is relatively expensive, but for some patients, this price is still acceptable compared to other imported drugs. The quality of the Indian version of the original Apelvis drug is guaranteed and the price is cheaper than similar drugs on the European and American markets. Therefore, many patients choose to import the drug from India, although this may involve a longer transportation period and additional costs.

In addition, generic versions of Apelvis are also available in overseas markets, and these generic versions usually significantly reduce prices by reducing production costs. The price of some generic drugs on the market is about more than 1,000 yuan, which is much cheaper than the original drugs. The emergence of generic drugs has provided a more economical choice for the majority of patients, especially in some high-income countries or regions, where the price of generic drugs can better meet patients' demand for drugs.

Although generic drugs are relatively inexpensive, patients still need to be cautious when choosing them. Although the quality of generic drugs is regulated and approved, there are still certain individual differences. When choosing whether to use generic drugs, it is recommended that patients do so under the guidance of a doctor to ensure the efficacy and safety of the drug. With the promotion of Apelvis in the global market, if the drug is launched in China in the future, the price may be further affected by market competition, thereby providing patients with more treatment options.

Reference materials:https://www.piqray.com/